Cancer Institute A national cancer institute
designated cancer center

Cancer Survivorship Studies

Building on advances in combined modality therapy, clinicians at Stanford are achieving a complete remission for more than 85% of all adult and pediatric patients treated for Hodgkin's disease. Despite this success, the long-term outcome of these patients is undermined by an increased risk for secondary cancer, cardiovascular disease, infections and pulmonary disease, among other complications. A number of studies are underway to address these long-term issues.

For example, researchers are analyzing factors such as radiation, chemotherapy and lifestyle exposures that may contribute to the onset of subsequent malignancies. As part of this work, researchers are evaluating the success of newer treatments for Hodgkin's disease that limit radiation and chemotherapy exposure.

Steven Hancock, MD

Sarah Donaldson, MD

Michael Link, MD

Sylvia Plevritis, PhD


Stanford Medicine Resources:

Footer Links: